CRC for Mental Health


Berk M, Nierenberg AA. (2015) Three paths to drug discovery in psychiatry. American Journal of Psychiatry172(5), 412-414.

Chatterjee P, Gupta VB, Fagen AM, Jasielec MS, Xiong C, Sohrabi HR, Dhaliwal S, Taddei K, Bourgeat P, Brown BM, Benzinger T, Bateman RJ, Morris JC, Martins RN et al (2015). Decreased platelet APP isoform ratios in autosomal dominant Alzheimer’s disease: baseline data from a DIAN cohort subset. 12: 157-164.

Davis J, Maes M, Andreazza A, McGrath JJ, Tye SJ, Berk M (2014) Towards a classification of biomarkers of neuropsychiatric disease: from encompass to compass. Mol Psychiatry doi: 10.1038/mp.2014.139.

Dean, B., & Scarr, E. (2015). Possible involvement of muscarinic receptors in psychiatric disorders: A focus on schizophrenia and mood disorders. Current molecular medicine.

Debnath M, Venkatasubramanian G, Berk M (2014) Fetal programming of schizophrenia: select mechanisms. Neurosci Biobehav Rev. 2014 Dec 10.

Gupta VB, Wilson AC, Burnham S, Hone E, Pedrini S, Laws SM, Lim WL, Rembach A, Rainey-Smith S, Ames D, Cobiac L, Macaulay SL, Masters CL, Rowe CC, Bush AI, Martins RN; AIBL Research Group (2015). Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. Alzheimer’s research & therapy, 7, 1-9.

Hamazaki K, Maekawa M, Toyota T, Dean B, Hamazaki T, Yoshikawa T (2015) Fatty acid composition of the postmortem prefrontal cortex of patients with schizophrenia, bipolar disorder, and major depressive disorder.  Psychiatry research227(2), 353-359.

Hare DJ, Doecke JD, Faux NG, Rembach A, Volitakis I, Fowler CJ, Grimm R, Doble PA, Cherny RA, Masters CL, Bush AI, Roberts BR (2015). Decreased plasma iron in Alzheimer’s disease is due to transferrin desaturation. ACS chemical neuroscience.

Hayley AC, Williams LJ, Venugopal K, Kennedy GA, Berk M, Pasco JA (2015). The relationships between insomnia, sleep apnoea and depression: Findings from the American National Health and Nutrition Examination Survey, 2005-2008. Australian and New Zealand journal of psychiatry, 49(2), 156-170.

Jablensky, A (2015). Schizophrenia or Schizophrenias? The Challenge of Genetic Parsing of a Complex Disorder. Am J Psychiatry, 172(2).Dipnall JF, Pasco JA, Meyer D, Berk M, Williams LJ, Dodd S, Jacka FN (2015). The association between dietary patterns, diabetes and depression. J Affect Disord 174, 215-224.

Lim YY, Villemagne VL, Pietrzak RH, Ames D, Ellis KA, Harrington K, Syner PJ, Martins RN, Masters CL, Rowe CC, Maruff P et al (2015). APOE E4 moderates amyloid-related memory decline in preclinical Alzheimer’s disease. Neurology of Aging 36: 1239-1244

Maes M, Nowak G, Caso JR, Leza JC, Song C, Kubera M, Klein H, Galecki P, Noto C, Glaab E, Balling R, Berk M (2015) Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research. Molecular neurobiology, 1-9.

Morris G, Berk M (2015) The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC medicine13(1), 68.

Morris G, Berk M, Walder K, Maes M (2015) The Putative Role of Viruses, Bacteria, and Chronic Fungal Biotoxin Exposure in the Genesis of Intractable Fatigue Accompanied by Cognitive and Physical Disability. Mol Neurobiol. 2015 Jun 17. [Epub ahead of print]

Nunes SO, Piccoli de Melo LG, Pizzo de Castro MR, Barbosa DS, Vargas HO, Berk M, Maes M (2015) Atherogenic index of plasma and atherogenic coefficient are increased in major depression and bipolar disorder, especially when comorbid with tobacco use disorder. Journal of Affective Disorders 172(2015)55–62.

Oliver G, Dean O, Camfield D, Blair-West S, Ng C, Berk M, Sarris J (2015) N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review. Clinical Psychopharmacology and Neuroscience13(1), 12.

Pizzo de Castro MR, Vargas Nunes SO, Guembarovski RL, Ariza CB, Oda JM, Vargas HO, Piccoli de Melo LG, Watanabe MA, Berk M, Maes M (2015) STin2 VNTR polymorphism is associated with comorbid tobacco use and mood disorders. Journal of Affective Disorders, 172: 347-354.

Rembach A, Stingo FC, Peterson C, Vannucci M, Do KA, Wilson WJ, Macaulay SL, Ryan TM, Martins RN, Ames D, Masters CL, Doecke JD, et al (2015) Bayesian graphical network analyses reveal complex biological interactions specific to Alzheimer’s disease. J Alzheimer’s Dis, 44:917-925.

Scarr E, Millan MJ, Bahn S, Bertolino A, Turck CW, Shitij Kapur S, Möller H-J, Dean B (2015) Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a report of the 2013 CINP Think-Tank.  International Journal of Neuropsychopharmacology, pyv042.

Slattery J, Kumar N, Delhey L, Berk M, Dean O, Spielholz C, Frye R (2015) Clinical Trials of N-acetylcysteine in Psychiatry and Neurology: A Systematic Review. Neuroscience & Biobehavioral Reviews.

Talarowska M, Szemraj J, Berk M, Maes M, Gałecki P (2015) Oxidant/antioxidant imbalance is an inherent feature of depression.  BMC psychiatry15(1), 71.

Vargas Nunes SO, Pizzo de Castro MR, Moreira EG, Guembarovski RL, Barbosa DS, Vargas HO, Piccoli de Melo LG, Bortolasci CC, Watanabe MA, Dodd S, Berk M, Maes M (2015) Association of paraoxonase (PON)1 activity, glutathione S-transferase GST T1/M1 and STin.2 polymorphisms with comorbidity of tobacco use disorder and mood disorders. Neuroscience Letters 2015; 585:132–137.

Waterdrinker A, Berk M, Venugopal K, Rapado-Castro M, Turner A, Dean OM (2015) Effects of N-Acetyl cysteine on suicidal ideation in bipolar depression. J Clin Psychiatry. 2015 May;76(5):e665.


Aish PR, Catterjee P, Verdile G, Gupta VB, Trengove RD, Martins RN (2014) Clearing the amyoid in Alzheimer’s: progress towards earlier diagnosis and effective treatments – an update for cliniciansNeurodegenerative disease management 4: 363-378.

Anderson G, Berk M, Dean O, Moylan S, Maes M (2014) Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications. CNS Drugs 28(1): 1-10.

Anderson G, Kubera M, Duda W, Lason W, Berk M, Maes M (2014) Increased IL-6 trans-signaling in depression: focus on the tryptophan catbolite pathway, melatonin and neuroprogression. Pharmacological Reports 65(6): 1647-54.

Aydemir O, Cubukçuoğlu Z, Erdin S, Taş C, Onur E, Berk M (2014) Oxidative stress markers, cognitive functions, and psychosocial functioning in bipolar disorder: an empirical cross-sectional study. Rev Bras Psiquiatr. 2014 Dec;36(4):293-7.

Berk M, Dean OM, Cotton SM, Jeavons S, Tanious M, Kohlmann K, Hewitt K, Moss K, Allwang C, Schapkaitz I, Robbins J, Cobb H, Ng F, Dodd S, Bush AI, Malhi GS (2014) The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Psychiatry 75(6): 628-36.

Bortolasci CC, Vargas HO. Souza-Nogueira A, Barbosa DS, Moreira EG, Nunes SO, Berk M, Dodd S, Maes M (2014) Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism-smoking interactions differentially predict the odds of major depression and bipolar disorder. Journal of Affective Disorders 159: 23-30.

Bortolasci CC, Vargas HO, Souza-Nogueira A, Gastaldello Moreira E, Vargas Nunes SO, Berk M, Dodd S, Barbosa DS, Maes M (2014) Paraoxonase (PON)1 Q192R functional genotypes and PON1 Q192R genotype by smoking interactions are risk factors for the metabolic syndrome, but not overweight or obesity. Redox Report 2014; 19(6): 232-241.

Bousman CA, Sarris J, Won ES, Chang HS, Singh A, Lee HY, Ham BJ, Tan CH, Lee MS, Ng CH (2014) Escitalopram Efficacy in Depression – A Cross-Ethnicity Examination of the Serotonin Transporter Promoter Polymorphism. Psychopharmacol 2014;34(5): 00-00.

Brown BB, Bourgeat P, Peiffer JJ, Burnham S, Laws SM, Rainey-Smith SR, Bartres-Faz D, Villemagne VL, Taddei K, Rembach A, Bush A, Ellis KA, Macaulay SL, Rowe CC, Ames D, Masters CL, Maruff P, Martins RN et al (2014) Influence of BDNF Val66Met on the relationship between physical activity and brain volume. 83: 1345-1352.

Burnham SC, Faux NG, Wilson W, Laws SM, Ames D, Bedo J, Bush AI, Doecke JD, Ellis KA, Head R, Jones G, Kiiveri H, Martins RN, Rembach A, Rowe C, Salvado O, Lance Macaulay S, Masters CL, Villemagne VL; Alzheimer’s Disease Neuroimaging Initiative; Australian Imaging, Biomarkers and Lifestyle Study Research Group (2014) A blood based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study. Molecular Psychiatry 19(4): 519-526.

Caine JM, Churches Q, Waddington L, Nigro J, Breheney K, Masters CL, Nuttall SD, Stretsov VA (2014) Design of non-aggregating variants of AB peptideBiochemical and Biophysical Research Communications 453: 449-454. 

Carvalho AF, Berk M, Hyphantis TN, McIntyre RS (2014) The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychotherapy and Psychomatics 83(2): 70-88.

Carvalho AF, Rocha DQ, McIntyre RS, Mesquita LM, Köhler CA, Hyphantis TN, Sales PM, Machado-Vieira R, Berk M (2014) Adipokines as emerging depression biomarkers: A systematic review and meta-analysis. J Psychiatr Res. 2014 Dec;59:28-37.

Cheng L, Doecke JD, Sharples RA, Villemagne VL, Fowler CJ, Rembach A, Martins RN, Rowe CC, Macaulay SL, Masters CL, Hill AF (2014). Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment. Mol Psychiatry.

Dean B, Tawadros N, Suk Seo MS, Jeon WJ, Everall I, Scarr E, Gibbons A (2014) Lower cortical serotonin 2A receptors in major depressive disorder, suicide and in rats after administration of imipramine. International Journal of Neuropsychopharmacology 17:895-906.

Dean OM, Turner A, Malhi GS, Ng C, Cotton S, Dodd S, Sarris J, Samuni Y , Tanious M, Dowling N, Waterdrinker A, Smith D, Berk M, (2014) Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression. Revista Brasileira de Psiquiatria, (AHEAD), 00-00.

Debnath M, Berk M (2014) Th17 pathway mediated immunopathogenesis of schizophrenia: mechanisms and implications. Schizoph Bull, 40: 1412-1421.

Deckersbach T, Peters AT, Sylvia L, Urdahl A, Magalhaes PV, Otto MW, Frank E, Miklowitz DJ, Berk M, Kinrys G, Nierenberg A (2014) Do comorbid anxiety disorders moderate the effects of psychotherapy for bipolar disorder? Results from STEP-BD. The American Journal of Psychiatry 171(2): 178-86.

Dipnall, JF, Berk, M, Jacka, FN, Williams, LJ, Dodd, S, & Pasco, JA (2014). Data Integration Protocol In Ten-steps (DIPIT): A new standard for medical researchers. Methods, 69(3), 237-246.

Faux NG, Rembach A, Wiley J, Ellis KA, Ames D, Fowler CJ, Martins RN, Pertile KK, Rumble RL, Trounson B, Masters CL, the AIBL Research Group, Bush AI (2014) An anemia of Alzheimer’s disease. Molecular Psychiatry doi:10.1038/mp.2013.178

Fernandes BS, Steiner J, Berk M, Molendijk ML, Gonzalez-Pinto A, Turck CW, Nardin P, Gonçalves CA (2014) Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Mol Psychiatry doi: 10.1038/mp.2014.117.

Graham KT, Martin-Iverson MT, Holmes NP, Jablensky A, Waters F (2014) Deficits in agency in schizophrenia and additional deficits in body image, body schema and internal timing in passivity symptoms Frontiers of Psychiatry Epub ahead of print 2014, doi: 10:3389/fpsyt.2014.00126.

Gusev A, Lee SH, Trynka G, Finucane H, Vilhjálmsson BJ, Xu H, Zang C, Ripke S, Bulik-Sullivan B, Stahl E; Kähler AK, Hultman CM, Purcell SM, McCarroll SA, Daly M, Pasaniuc B, Sullivan PF, Neale BM, Wray NR,Raychaudhuri S, Price AL; Schizophrenia Working Group of the Psychiatric Genomics Consortium; SWE-SCZ Consortium (2014). Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases. The American Journal of Human Genetics, 95(5), 535-552.

Hare DJ, Lei P, Ayton S, Roberts BR, Grimm R, George JL, Bishop DP, Beavis AD, Donovan SJ, McColl G, Volitakis I, Masters CL, Adlard PA, Cherny RA, Bush AI, Finkelstein DI, Doble PA (2014) An iron-dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta. Chemical Science 5: 2160-2169.

Hayley AC, Williams LJ, Kennedy GA, Berk M, Brennan SL, Pasco JA (2014). Excessive daytime sleepiness and body composition: a population-based study of adultsPloS one, 9(11), e112238.

Hayley AC, Williams LJ, Kennedy GA, Berk M, Brennan SL, Pasco JA (2014). Excessive daytime sleepiness and metabolic syndrome: a cross-sectional studyMetabolism, 64(2), 244-252.

Hung YH, Faux NG, Killilea DW, Yanjamin N, Firnkes S, Volitakis I, Ganio G, Walterfang M, Hastings C, Porter FD, Ory DS, Bush AI (2014) Altered transition metal homeostasis in Niemann-Pick disease, Type C1. Metallomics 6: 542-53.

Jablensky A, Waters F (2014) RDoC: a road to pathogenesis? World Psychiatry 2014, 13:43-44.

Jiang, Z, Du, C, Jablensky, A, Liang, H, Lu, Z, Ma, Y, & Teo, KL (2014). Analysis of Schizophrenia Data Using A Nonlinear Threshold Index Logistic Model. PloS one, 9(10), e109454.

Johnson P, Vandewater L, Wilson W, Maruff P, Savage G, Graham P, Macaulay LS, Ellis KA, Szoeke C, Martins RN, Rowe CC, Masters CL, Ames D, Zhang P (2014). Genetic algorithm with logistic regression for prediction of progression to Alzheimer’s disease. BMC bioinformatics, 15(Suppl 16), S11.

Kapczinski F, Magalhães PV, Balanzá-Martinez V, Dias VV, Frangou S, Gama CS, Gonzalez-Pinto A, Grande I, Ha K, Kauer-Sant’Anna M, Kunz M, Kupka R, Leboyer M, Lopez-Jaramillo C, Post RM, Rybakowski JK, Scott J, Strejilevitch S, Tohen M, Vazquez G, Yatham L, Vieta E, Berk M (2014) Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report. Acta Psychiatr Scand. 2014 Nov;130(5):354-63.

Kim SW, Schäfer MR, Klier CM, Berk M, Rice S, Allott K, Bartholomeusz CF, Whittle SL, Pilioussis E, Pantelis C, McGorry PD, Amminger GP (2014) Relationship between membrane fatty acids and cognitive symptoms and information processing in individuals at ultra-high risk for psychosis. Schizophr Res. 2014 Sep;158(1-3):39-44.

Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Snyder PF, Ames D, Ellis KA, Harrington K, Rembach A, Martins RN, Rowe CC, Masters CL, Maruff P (2014) APOE and BDNF polymorphisms moderate amyloid B-related cognitive decline in pre-clinical Alzheimer’s disease. Molecular Psychiatry.

Maes M, Anderson G, Kubera M, Berk M (2014) Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opinion on Therapeutic Targets 18(5): 495-512.

Malhi GS, Berk M (2014) Diagnosing bipolar disorder: Defining thresholds and setting boundaries. Australian and New Zealand Journal of Psychiatry 48(500): 500-504.

Maruff P, Masters C, Ames D, Bush A, Rowe C, Villemagne V, Ellis K, Harrington K, Lim YY (2014) Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer’s disease: A preliminary study. PLoS One 9: e86498-e86502.

McGorry P, Keshavan M, Goldstone S, Amminger P, Allott K, Berk M, Lavoie S, Pantelis C, Yung A, Wood S, Hickie I (2014) Biomarkers and clinical staging in psychiatry. World Psychiatry. 2014 Oct;13(3):211-23.

Moore EM, Ames D, Mander AG, Carne RP, Brodaty H, Woodward MC, Boundy K, Ellis KA, Bush AI, Faux NG, Martins RN, Masters CL, Rowe CC, Szoeke C, Watters DA (2014) Among vitamin B12 deficient older people, high folate levels are associated with worse cognitive function: combined data from three cohorts. Journal of Alzheimer’s Disease 39: 661-8.

Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, Woodward M, Ellis KA, Bush AI, Faux NG, Watters DA (2014) Response to comment on Moore et al, Increased risk of cognitive impairment in patients with diabetes is associated with metformin, Diabetes care 36: 2981-2987. Diabetes Care 37: e151. doi: 10.2337/dc14-0278.

Morris G, Anderson G, Dean O, Berk M, Galecki P, Martin-Subero M, Maes M (2014) The glutathione system: a new drug target in neuroimmune disorders. Mol Neurobiol 50: 1059-1084.

Moylan S, Berk M, Dean OM. Samuni Y, Williams LJ, O’Neil A, Hayley AC, Pasco JA, Anderson G, Jacka FN, Maes M (2014) Oxidative & nitrosative stress in depression: Why so much stress? Neuroscience and Biobehavioral Reviews 45C: 46-62.

Nabavi SF, Turner A, Dean O, Sureda A, Mohammad S (2014) Post-stroke Depression Therapy: Where are we now? Current Neurovascular Research, 2014, 11, 00-00.

O’Neil A, Quirk SE, Housden S, Brennan SL, Williams LJ, Pasco JA, Berk M, Jacka FN (2014). Relationship between diet and mental health in children and adolescents: a systematic reviewAmerican journal of public health, 104(10), e31-e42.

Opazo CM, Greenough MA, Bush AI (2014) Copper: From neurotransmission to neuroproteostasis. Frontiers in Aging Neuroscience 6: 143.

Pietrzak RH, Lim YY, Ames D, Harrington K, Restrepo C, Martins RN, Rembach A, Laws SM, Masters CL, Villemagne VL, Rowe CC, Maruff P;Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group (2014). Trajectories of memory decline in preclinical Alzheimer’s disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Neurobiology of aging, 36 (3) (2015), pp. 1231–1238

Pizzo de Castro MR, Maes M1, Guembarovski RL, Ariza CB, Reiche EM, Vargas HO, Vargas MM, de Melo LG, Dodd S, Berk M, Watanabe MA, Nunes SO (2014) SLC6A4 STin2 VNTR genetic polymorphism is associated with tobacco use disorder, but not with successful smoking cessation or smoking characteristics: a case control study. BMC Genetics 2014, 15:78.

Quirk SE, El-Gabalawy R, Brennan SL, Bolton JM, Sareen J, Berk M, Chanen AM, Pasco JA, Williams LJ (2014). Personality disorders and physical comorbidities in adults from the United States: data from the National Epidemiologic Survey on Alcohol and Related ConditionsSocial psychiatry and psychiatric epidemiology, 1-14.

Quirk SE, El-Gabalawy R, Brennan SL, Bolton J, Sareen J, Berk M, Chanen A, Pasco JA, Williams LJ (2014). Personality disorders and physical comorbidities in adults from the United States: Data from the National Epidemiological Survey on Alcohol and Related Conditions. Social Psychiatry and Social Epidemiology, 1-14.

Rapado-Castro M, Berk M, Venugopal K, Bush AI, Dodd S, Dean OM (2014) Towards stage specific treatments: effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 57:69-75.

Redlich C, Berk M, Williams LJ, Sundquist J, Sundquist K, Li X (2014). Statin use and risk of depression: a Swedish national cohort studyBMC psychiatry, 14(1), 348.

Rembach A, Hare DJ, Doecke JD, Burnham SC, Volitakis I, Fowler CJ, Cherny RA, McLean C, Grimm R, Martins R, Ames D, Masters CL, Bush AI, Roberts BR (2014) Decreased serum zinc is an effect of ageing and not Alzheimer’s disease. Metallomics 6: 1216-1219.

Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Roberts BR, Perez KA, Li Q-X, Laws SM, Taddei K, Rainey-Smith S, Robertson JS, Vandijck M, Vanderstichele H, Barnham KJ, Ellis KL, Szoeke C, Macaulay LS, Rowe CC, Villemagne VL, Ames D, Martins RN, Bush AI, Masters CL (2014) Changes in plasma beta-amyloid in a longitudinal study of aging and Alzheimer’s disease. Alzheimer’s and Dementia 10(1): 53-61.

Rembach A, Watt AD, Wilson WJ, Rainey-Smith S, Ellis KA, Rowe CC, Villemagne VL, Macaulay SL, Bush AI, Martins RN, Ames D, Masters CL, Doecke JD, et al (2014). An increased neutrophil-lymphocyte ratio in Alzheimer’s disease is a function of age and is weakly correlated with neocortical amyloid accumulation. J Neuroimmunol, 273:65-71.

Rembach A, Watt AD, Wilson WJ, Villemagne VL, Burnham SC, Ellis KA, Maruff P, Ames D, Rowe CC, Macaulay SL, Bush AI, Martins RN, Masters CL, Doecke JD, AIBL Research Group (2014) Plasma Aβ levels are significantly associated with a transition towards Alzheimer’s disease as measured by cognitive decline and change in neocortical amyloid burden. Journal of Alzheimer’s disease 40(1): 95-104.

Ripke S, … Jablensky A et al [multi-authored publication], Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature,511(7510), 421-427.

Sanna L, Stuart AL, Pasco JA, Jacka FN, Berk M, Maes M, O’Neil A, Paolo G, Williams LJ (2014) Atopic disorders and depression: Findings from a large, population-based study. Journal of Affective Disorders 155: 261-265.

Seo MS, Scarr E, Dean B (2014). An investigation of the factors that regulate muscarinic receptor expression in schizophrenia. Schizophrenia Research 158: 247-254.

Seo MS, Scarr E, Lai CY, Dean B (2014) Potential molecular and cellular mechanism of psychotropic drugs. 12: 94-110.

Singh AB, Bousman CA, Ng C, Berk M (2014) Antidepressant pharmacogenetics. Current Opinion in Psychiatry 27(1): 43-51.

Squitti R, Simonelli I, Ventriglia M, Siotto M, Pasqualetti P, Rembach A, Doecke J, Bush AI (2014) Meta-analysis of serum non-ceruloplasmin copper in Alzheimer’s disease. Journal of Alzheimer’s Disease 38(4): 809-22.

Stefanis NC, Dragovic M, Power BD, Jablensky A, Castle D, Morgan V, (2014) The effect of drug use on the age at onset of psychotic disorders in an Australian cohort. Schizophrenia Research 2014, 156:211-216.

Vargas HO, Vargas Nunes SO, Barbosa DS, Vargas MM, Certari A, Dodd S, Venugopal K, Maes M, Berk M (2014) Castelli risk indexes 1 and 2 are higher in major depression but other characteristics of the metabolic syndrome are not specific to mood disorders. Life Sciences 102(1): 65-71.

Wang Y, Zhang H, Chai F, Liu X, Berk M (2014) The effects of escitalopram on myocardial apoptosis and the expression of Bax and Bcl-2 during myocardial ischemia/reperfusion in a model of rats with depression. BMC Psychiatry. 2014 Dec 4;14(1):349.

Wang Y, Zhang H, Tang S, Liu X, O’Neil A, Turner A, Chai F, Chen F, Berk M (2014) Assessing regional cerebral blood flow in depression using 320-slice computed tomography. PLoS One. 2014 Sep 24;9(9):e107735.


Wong BXW, Hung YH, Bush AI, Duce JA (2014) Metals and cholesterol: two sides of the same coin in Alzheimer’s disease pathology. Frontiers in Aging Neuroscience 6: 91.


Berk M, Berk L, Dodd S, Fitzgerald PB, de Castella AR, Filia S, Filia K, Brnabic AJM, Kelin K, Montgomery W, Kulkarni J, Stafford L (2013) The sick role, illness cognitions and outcomes in bipolar disorder. Journal of Affective Disorders, 146: 146-149.

Berk M, Jacka FN, Williams LJ, O’Neil A, Pasco J, Moylan S, Allen N, Stuart A, Hayley A, Byrne M, Maes M (2013) So depression is an inflammatory disease, but where does the inflammation come from? BMC Medicines, 11(1): 1-16.

Berk M, Malhi GS, Gray LJ, Dean OM (2013) The promise of N-acetylcysteine in psychiatry. Trends in Pharmacological Sciences 34(3):167-177.

Brown BM, Peiffer JJ, Taddei K, Lui JK, Laws SM, Gupta VB, Taddei T, Ward VK, Rodrigues MA, Burnham S, Rainey-Smith SR, Villemagne VL, Bush AI, Ellis KA, Masters CL, Ames D, Macaulay SL, Szoeke C, Rowe CC, Martins RN, and the AIBL Research Group (2013) Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Molecular Psychiatry 18, 875-881.

Chana G, Bousman CA, Money TT, Gibbons A, Gillett P, Dean B, Ian Paul Everall IP (2013) Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis. Frontiers in Cellular Neuroscience 7: 95.

Dean B, Moller H-J, Svensson TH, Geyer MA, Rujescu D, Scarr E, Millan MJ (2013) Problems and solutions to filling the drying drug pipeline for psychiatric disorders: a report from the inaugural 2012 CINP think-tank. International Journal of Neuropyschopharmacology 17:137-148.

Ellis KA, Lim YY, Harrington K, Ames D, Bush AI, Darby D, Martins RN, Masters CL, Rowe CC, Savage G, Szoeke C, Villemagne VL, Maruff P (2013) Decline in cognitive function over 18 months in healthy older adults with high amyloid-beta. Journal of Alzheimer’s Disease 34(4): 861-871.

Ellis KA, Szoeke C, Bush AI, Darby D, Graham PL, Lautenschlager NT, Macaulay SL, Martins RN, Maruff P, Masters CL, McBride SJ, Pike KE, Rainey-Smith SR, Rembach A, Robertson J, Rowe CC, Savage G, Villemagne VL, Woodward M, Wilson W, Zhang P, Ames D, and the AIBL research group (2013) Rates of diagnostic transition and cognitive change at 18 month follow up among 1112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). International Psychogeriatrics 26(4): 543-54.

Fernandes BS, Berk M, Turck CW. Steiner J, Goncalves CA (2013) Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis. Molecular Psychiatry 19: 750-751.

Frey BN, Andreazza AC, Frye MA, Goldstein BI, Malhi GS, Hall GB, Taylor VH, Fernandes BS, Kauer-Sant’Anna M, Dodd S, Lopez-Jaramillo C, Leboyer M, Frangou S Yatham LN, Berk M, Yound T, Kapczinski F (2013) Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Commitee. Australian and New Zealand Journal of Psychiatry, 47: 321-332.

Ghanizadeh A, Berk M (2013) Molecular hydrogen: an overview of its neurobiological effects and therapeutic potential for bipolar disorder and schizophrenia. Medical Gas Research 3(1): 11.

Gibbons AS, Scarr E, Boer S, Money T, Jeon W-J, Felder C, Dean B (2013) Widespread decreases in cortical muscarinic receptors in a sub-set of people with schizophrenia. International Journal of Neurospsychopharamcology, 16: 37-46.

Gupta VB, Sundaram R, Martins RN (2013) Multiplex biomarkers in blood. Alzheimer’s Research & Therapy, 5: 31.

Hare D, Grubman A, Ryan TM, Lothian A, Liddell JR, Grimm R, Matsuda T, Doble PA, Cherney RA, Bush AI, White AR, Masters CL, Roberts BR (2013) Profiling the iron, copper and zinc content in primary neuron and astrocyte cultures by online quantitative size exclusion chromatography-inductively coupled plasma-mass spectrometry. Metallomics 5(12): 1656-1662.

Jeon WJ, Gibbons AS, Dean B (2013) The use of a modified [H]4-DAMP radioligand binding assay with increased selectivity for muscarinic M3 receptor shows that cortical CHRM3 levels are not altered in mood disorders. Progress in neuro-psychopharmacology and biological psychiatry 47: 7-12.

Lauder S, Chester A, Castle D, Dodd S, Berk L, Klein B, Austin D, Gilbert M, Chamberlain JA, Murray G, White C, Piterman L, Berk M (2013) Development of an online intervention for bipolar disorder, Psychology, Health & Medicine, 18.

Laws SM, Doeke JD, Martins (2013) Blood-based biomarkers in Alzheimer’s disease: where are we now and where have we to go? – Reply. Neurology, 70: 133-134.

Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA, Harrington KD, Bourgeat P, Salvado O, Darby D, Snyder PJ, Bush AI, Martins RN, Masters CL, Rowe CC, Nathan PJ, Maruff P, Australian Imaging Biomarkers and Lifestyle Study of Ageing research group (2013) BDNF Val66Met, AB amyloid, and cognitive decline in preclinical Alzheimer’s disease. Neurobiology of Aging 34: 2457-2464.

Lim YY, Jaeger J, Harrington K, Ashwood T, Ellis KA, Stöffler A, Szoeke C, Lachovitzki R, Martins RN, Villemagne VL, Bush AI Masters CL, Rowe CC, Ames D, Darby D, Maruff P (2013) Three month stability of the CogState brief battery in healthy older adults, mild cognitive impairment and Alzheimer’s disease: Results from the Australian Imaging, Biomarkers and Lifestyle – Rate of Change sub-study (AIBL-ROCS). Archives of Clinical Neuropsychology 28(4): 320-330.

Lothian A, Hare D, Masters C, Ryan T, Grimm R, Roberts BR (2013) Metalloproteomics: Principles, challenges and applications to neurodegeneration. Frontiers in Aging Neuroscience 5:35.

Moller M, Du Preez JL, Vilijoen FP, Berk M, Emsley R, Harvey BH (2013) N-Acetyl cysteine reverses social isolation rearing induced changes in cortico-striatal monoamines in rats. Metabolic Brain Disease 28(4): 687-96.

Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, Woodward M, Boundy K, Ellis KA, Bush AI, Faux NG, Martins R, Szoeke C, Rowe C, Watters DA; AIBL Investigators (2013). Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care 36: 2981-87. Erratum in: Diabetes Care 36: 3850.

Morris G, Anderson G, Berk M, Maes M (2013) Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications. Molecular Neurobiology 48(3): 883-903.

Nisbet RN, Nuttall SD, Caine JM, Robert R, Hittaki M, Pearce LA, Davydova N, Masters CL, Varghese JN, Streltsov VA (2013) Structural studies of the tethered N-terminus of the Alzheimer’s disease AB peptide. Proteins: Structure, Function and Bioinformatics, 81: 1748-1758.

Peters C, Fernandez-Perez EJ, Burgos CF, Espinoza MP, Castillo C, Urrutia JC, Streltsov VA, Opazo C, Aguayo LG (2013) Inhibition of the synaptotoxicity induced by Aβ oligomers by a pentapeptide derived from the glycine zipper region of the Aβ peptide. Neurobiology of Aging 34(12): 2805-2814.

Ripke S et al. [including Jablensky A]. (2013) Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nature Genetics, 45.10 (2013): 1150-1159.

Ripke S et al. [including Jablensky A] (2013).Genome-wide association analysis identifies 13 new risk loci for schizophreniaNature Genetics 45: 1150-1159.

Rembach A, Doecke JD, Roberts BR, Watt AD, Faux NG, Volitakis I, Pertile KK, Rumble RL, Trounson BO, Folwer CJ, Wilson W, Ellis KA, Martins RN, Rowe CC, Villemagne VL, Ames D, Masters CL, Bush AI (2013) Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer’s Disease. Journal of Alzheimer’s Disease, 34:171-182

Rembach A, Ryan T, Roberts B, Doecke J, Wilson W, Watt A, Barnham K, Masters C (2013) Progress towards consensus biomarkers for Alzheimer’s disease: a review of peripheral–based analytes. Biomarkers in Medicine 7: 1-22.

Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, Jones G, Maruff P, Woodward M, Price R, Robins P, Tochon-Danguy H, O’Keefe G, Pike KE, Yates P, Szoeke C, Salvado O, Macaulay SL, O’Meara T, Head R, Cobiac L, Savage G, Martins R, Masters CL, Ames D, Villemagne VL (2013) Predicting Alzheimer’s disease with beta-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageingAnnals of Neurology 74: 905-913.

Ryan TM, Caine J, Mertens HDT, Kirby N, Nigro J, Breheney K, Waddington LJ, Streltsov VA, Curtain C, Masters CL, Roberts BR (2013) Ammonium hydroxide treatment of Aβ produces an aggregate free solution suitable for biophysical and cell culture characterization. PeerJ, DOI 10.7717/peerj.73.

Sanna L, Stuart AL, Pasco JA, Kotowicz MA, Berk M, Girardi P, Brennan SL, Williams LJ (2013) Physical comorbidities in men with mood and anxiety disorders: a population-based study. BMC Medicine 11:110.

Scarr E, Craig JM, Cairns MJ, Seo MS, Galati JC, Beveridge NJ, Gibbons A, Juzva S, Weinrich B, Parkinson-Bates M, Carroll AP, Saffery R, Dean B (2013) Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA. Translational Psychiatry 3, e230.

Scarr E, Um JY, Cowie TF, Dean B (2013) Cholinergic muscarinic M4 receptor gene polymorphisms; a potential risk factor and pharmacogenomic marker for schizophrenia. Schizophrenia Research 146: 279-284.

Schork AJ et al. [including Jablensky A] (2013) All SNPs are not created equal: genome-wide association studies reveal a consistent pattern of enrichment among functionally annotated SNPs. PLoS Genetics 9.4: e1003449.

Streltsov VA, Epa VC, James SA, Churches QI, Caine JM, Kenche VB, Barnham KJ (2013) Structural insights into the interaction of platinum-based inhibitors with the Alzheimer’s disease amyloid-β peptide. Chemical Communications 49: 11364-11366.

Sumani Y, Goldstein S, Dean OM, Berk M (2013) The chemistry and biological activities of Nacetylcysteine. Biochimica et Biophysica Acta 1830: 4117–4129.

Terwisscha van Scheltinga AF et al. [including Jablensky A] (2013) Genetic schizophrenia risk variants jointly modulate total brain and white matter volume. Biological Psychiatry 73: 525-531.

Vargas HO, Nunes SO, Pizzo de Castro M, Cristina Bortolasci C, Sabbatini Barbosa D, Kaminami Morimoto H, Venugopal K, Dodd S, Maes M, Berk M (2013) Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. Journal of Affective Disorders 150(3): 923-30.

Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins RN, Maruff P, Ames D, Rowe CC, Masters CL, for the Australian Imaging Biomarkers and Lifestyle Research Group (2013) Aβ deposition, neurodegeneration and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurology 12: 357-367.



Anderson G, Maes M, Berk M (2012) Biological underpinnings of the commonalities in depression, somatisation and chronic fatigue syndrome. Medical Hypotheses, 78: 752-753.

Anderson G, Maes M, Berk M (2012) Inflammation-related disorders in the tryptophan catabolite pathway in depression and somatization. Advances in Protein Chemistry and Structural Biology, 88: 27-48.

Anderson RJ, Frye MA, Lee KH, McGillivray JA, Berk M, Tye SJ (2012) Deep brain stimulation for treatment-resistant depression: efficacy, safety and mechanisms of action. Neuroscience and Biobehavioral Reviews, 36: 1920-1933.

Bauer M, Glenn T, Alda M, Andreassen OA, Ardau R, Berk M et al (2012) Impact of sunlight on the age of onset of bipolar disorder, 14: 654-663.

Bechdolf A, Ratheesh A, Wood J, Tecic T, Conus P, Nelson B, Cotton S, Chanen A, Amminger G, Ruhrmann S, Schultze-Lutte F, Klosterkotter J, Fusar Poli P, Yung AR, Berk M, McGorry PD (2012) Rationale and first results of developing at-risk (prodromal) criteria for bipolar disorder. 18: 358-375.

Bechdolf A, Wood SJ, Nelson B, Velakoulis D, Yucel M, Takahashi T, Yung AR, Berk M, Wong WT, Pantelis C, McGorry PD (2012) Amygdala and insula volumes prior to illness onset in bipolar disorder: a magnetic resonance imaging study. Psychiatry Research, 201: 34-39.

Berk M (2012) Is Australian psychiatry getting SHIP shape? Australian and New Zealand Journal of Psychiatry, 46: 801-802.

Berk M, Berk L, Davey CG, Moylan S, Giorlando F, Singh AB, Kalra H, Dodd S, Malhi GS (2012) Treatment of bipolar depression, MJA Open, 1: 32-35.

Berk M, Berk L, Dodd S, Jacka FN, Fitzgerald B, de Castella AR, Fillia S, Dillia K, Kulkarni J, Jackson HJ, Stafford L (2012) Psychometric properties of a scale to measure investment in the sick role: the Illness Cognitions Scale, Journal of Evaluation in Clinical Practice, 18: 360-364.

Berk M, Berk L, Udina M, Moylan S, Stafford L, Hallam K, Goldstone S, McGorry PD (2012) Palliative models of care for later stages of mental disorder: maximizing recovery, maintaining hope, and building morale, Australian and New Zealand Journal of Psychiatry, 46: 92-99.

Berk M, Dean OM, Cotton SM, Gama CS, Kapczinski F, Fernandes B, Kohlmann K, Jeavons S, Hewitt K, Moss K, Allwang C, Schapkaitz I, Cobb H, Bush AI, Dodd S, Malhi GS (2012) Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomised placebo controlled trial, BMC Medicine 10: 91.

Berk M, Jacka F (2012) Preventive strategies in depression: gathering evidence for risk factors and potential interventions. British Journal of Pharmacology, 201: 339-341.

Bromberg A, Lerer E, Udawela M, Scarr E, Dean B, Belmaker RH, Ebstein R, Agam G (2012) Nicotinamide-N-methyltransferase (NNMT) in schizophrenia: genetic association and decreased frontal cortex mRNA levels. International Journal of Neuropyschopharamcology, 15: 727-737.

Chetelat G, Rowe CC, Villemagne VL. (2012) Amyloid Imaging in Alzheimer’s Disease: Relationships to Memory Deficits, Brain Atrophy, and Hypometabolism. European Neurological Journal 4: 61-68.

Chetelat G, Villemagne VL, Pike KE, Ellis KA, Ames D, Masters CL, Rowe CC (2012) Relationships between memory performances and [beta]-amyloid deposition at different stages of Alzheimer’s disease. Neurodegenerative Diseases, 10: 141-144.

Chetelat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, Martins RN, Masters CL, Rowe CC (2012) Accelerated cortical atrophy in cognitively normal elderly with high [beta]-amyloid deposition. Neurology, 78: 477-484.

Conn CE, Darmanin C, Mulet X, Hawley A, Drummond CJ (2012) Effect of lipid architecture on cubic phase susceptibility to crystallisation screens. Soft Matter, 8: 6884-6896.

Conn CE, Darmanin C, Mulet X, LeCann S, Kirby N, Drummond CJ (2012) High-throughput analysis of the structural evolution of the monoolein cubic phase in situ under crystallogenesis conditions. Soft Matter, in print.

Cotton SM, Lambert M, Schimmelmann BG, Gleeson JFM, Berk M, Hides L, Chanen A, McGorry PD, Conus P (2012) Depressive symptoms in first episode schizophrenia spectrum disorder. Schizophrenia Research, 134: 20-26.

Darmanin C, Conn CE, Newman J, Mulet X, Seabrook SA, Liang Y-L, Hawley A, Kirby N, Varghese JN, Drummond CJ (2012) High-throughput production and structural characterisation of libraries of self-assembly lipidic cubic phase materials. ACS Combinatorial Science, 14: 247-252.

Dean B (2012) Editorial: Cholinergic muscarinic receptors: New opportunities as drug targets to treat psychiatric disorders. Future medicinal chemistry, 5: 1-3.

Dean B (2012) Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia. Current Pharmaceutical Biotechnology, 13: 1563-1571.

Dean B (2012) Neurochemistry of schizophrenia and psychosis: the contribution of neuroimaging. Current topics in medicinal chemistry, 12: 2375-2392.

Dean OM, Bush AI, Berk M (2012) Translating the Rosetta stone of N-acetyl cysteine. Biological Psychiatry, 71: 935-996.

Dean OM, Bush AI, Copolov DL, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hun M, Berk M (2012) Effects of N-acetyl cysteine on cognitive function in bipolar disorder. Psychiatry and Clinical Neurosciences, 66: 514-517.

Dean OM, Data-Franco J, Giorlando F, Berk M (2012) Minocycline: therapeutic potential in psychiatry. CNS Drugs, 26: 391-401.

Djang DS, Janssen MJ, Bohnen N, Booij J, Henderson TA, Herholz K, Minoshima S, Rowe CC, Sabri O, Seibyl J, Van Berckel BN, Wanner M (2012) SNM practice guideline for dopamine transporter imaging with 123O-Ioflupane SPECT. Protein Science, 20:457-464.

Doeke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN, Alzheimer’s Disease Neuroimaging Initiative, Australian Imaging Biomarkers and Lifestyle Study of Ageing (2012) Blood-based protein biomarkers for diagnosis of Alzheimer’s disease. Archives of Neurology, 69: 1318-1325.

Epa V, Streltsov V, Varghese J (2012) Computational studies on the stability of C-terminal beta-amyloid dimer and mutants. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 8: 718.

Green MJ, Cairns MJ, Wu, J, Dragovic M, Jablensky A, Tooney PA, Scott RJ, Carr VJ (2012) Genome-wide supported variant MIR317 and severe negative symptoms predict membership of an impaired cognitive subtype of schizophrenia. Molecular Psychiatry.

Jablensky A (2012) The disease entity in psychiatry: fact or fiction? Epidemiology and Psychiatric Services, 21: 255-264

Jacka FN, Berk (2012) Depression, diet and exercise. MJA Open, 1: 21-23.

Jacka FN, Maes M, Pasco JA, Williams LJ, Berk M (2012). Nutrient intakes and the common mental disorders in women. Journal of Affective Disorders. Epub ahead of publication.

Jacka FN, Pasco JA, Williams LJ, Mann N, Hodge A, Brazionis L, Berk M (2012). Red meat consumption and mood and anxiety disorders. Pyschotherapy and Pyschosomatics, 81: 196-198.

Macneil CA, Hallam K, Conus P, Henry L, Kader L, Berk M (2012) Are we missing opportunities for early intervention in bipolar disorder? Expert Review Neurotherapy, 12: 5-7.

Maes M, Berk M, Goehler L, Song C, Anderson G, Galecki P, Leonard B (2012) Depression and sickness behaviour are Janus-faced responses to shared inflammatory pathways. BMC Medicine, 29: 66.

Maes M, Fisar Z, Medina M, Scapagnini G, Nowak G, Berk M (2012) New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant and neuroprogressive pathways and new drug candidates- NRF2 activators and GSK-3 inhibitors. Inflammopharmcology, 20: 127-150.

Maes M, Kubera M, Leunis JC, Berk M (2012) Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased translocation or leaky gut. Journal of Affective Disorders.

Maes M, Kubera M, Leunis JC, Berk M, Geffard M, Bosmans E (2012) In depression, bacterial translocation may drive inflammatory responses directed against O&NS-damaged neoepitopes. Acta Psychiatrica Scandinavica.

Maes M, Kubera M, Mihaylova I, Geffard M, Galecki P, Leunis JC, Berk M (2012) Increased autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: implications for the pathways to chronic depression and neuroprogression. Journal of Affective Disorders

Maes M, Ringel K, Kubera M, Berk M, Rybakowski J (2012) Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. Journal of Affective Disorders., 136: 386-392.

Magalhaes PVS, Dean O, Andreazza AC, Berk M, Kapczinski F (2012) Adjunctive antioxidants for bipolar disorder (Protocol). Cochrane Review.

Magalhaes PV, Dean OM, Bush AI, Copolov DL, Weisinger D, Malhi GS, Kolmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M (2012) Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder. Progress in Neuro-Psychophamacology and Brain Psychiatry, 37: 132-135.

Magalhaes PV, Dodd S, Nierenberg AA, Berk M (2012) Cumulative morbidity and prognostic staging of illness in the systematic treatment enhancement program for bipolar disorder (STEP-BD) Australian & New Zealand Journal of Psychiatry, 46: 1017-1018.

Magalhaes PV, Kapczinski F, Nierenberg AA, Deckersbach T, Weisinger D, Dodd S, Berk M (2012) Illness burder and medical comordibity in the systematic treatment enhancement program for bipolar disorder. Acta Psychiatrica Sandinavica, 125: 303-308.

Malhi GS, Bargh DM, McIntye R, Gitlin M, Frye MA, Bauer M, Berk M (2012) Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder. Bipolar Disorders, 14: 1-21.

Malhi GS, Berk M (2012) Is the safety of lithium no longer in the balance? Lancet, 379: 690-692.

Malhi GS, Tanious M, Das P, Berk M (2012) The science and practice of lithium therapy Australian New Zealand Journal of Psychiatry, 46: 192-211.

Macneil CA, Hasty M, Cotton S, Berk M, Hallam K, Kader L, McGorry P, Conus P (2012) Can a targeted psychological intervention be effective for young people following a first manic episode? Results from an 18-month pilot study, Early Intervention in Psychiatry, 6: 380-388.

Markanday S, Data-Franco J, Dyson L, Murrant S, Arbuckle C, McGillvray J, Berk M (2012) Acceptance and commitment therapy for treatment-resistant depression. Bipolar Disorders, 46: 1198-1199.

Maud C, Berk M (2012) Neuropsychiatric presentation of Lyme disease in Australia Australian New Zealand Journal of Psychiatry.

McGorry PD, Berk M, Berk L, Goldstone S (2012) Commentary on ‘Palliative models of car for later stages of mental disorder: Maximising recovery, maintaining hope and building morale’, Australian New Zealand Journal of Pyschiatry, 46: 276-278.

Moylan S, Giorlando F, Nordfjaern T, Berk M (2012) The role of alprazolam for the treatment of panic disorder in Australia. Australian New Zealand Journal of Pyschiatry, 46: 212-224.

Moylan S, Maes M, Wray NR, Berk M (2012) The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Molecular Psychiatry 18: 595-606.

Nunes SO, Vargas HO, Brum J, Prado E, Bargas MM, de Castro MR, Dodd S, Berk M (2012) A comparison of inflammatory markers in depressed and nondepressed smokers. Nicotine Tobacco Research, 14: 540-546.

Pasco JA, Jacka FN, Williams LJ, Evans-Cleverdon M, Brennan SL, Kotowicz MA, Nicholson GC, Ball MJ, Berk M (2012) Dietary selenium and major depression: a nested case-control study. Complementary Therapies in Medicine, 20: 119-193.

Sarris J, Moylan S, Camfield DA, Pase MP, Mischoulon D, Berk M, Jacka FN, Schweitzer I (2012) Complementary medicine, exercise, meditation, diet and lifestyle modification for anxiety disorders: a review of current evidence. Evidence-based complementary and alternative medicine.

Scarr E (2012) Muscarinic M1 receptor agonists: can they improve cognitive performance in humans? International Journal of Neuropyschophamacology.

Scarr E (2012) Muscarinic receptors: Their roles in disorders of the central nervous system and potential as therapeutic targets. CNS Neuroscience & Therapeutics, 18: 369-379.

Scarr E, Dean B (2012) Altered neuronal markers following treatment with mood stabliser and antipsychotic drugs indicate an increased likelihood of neurotransmitter release. Clinical Pyschopharmacology and Neuroscience, 10: 25-33.

Scarr E, Money TT, Pavey G, Neo J, Dean B (2012) Mu opioid receptor availability in people with psychiatric disorders who died by suicide: a case control study. BMC Pyschiatry 12: 126.

Scarr E, Sundram S, Dejo A, Cowie TF, Gibbons AS, Juva S, Mackinnon A, Wood SJ, Testa R, Pantelis C, Dean B (2012) Muscarinic M1 receptor sequence: Preliminary studies on its effects on cognition and expression. Schizophrenia Research, 138: 94-98.

Sona A, Zhang P, Ames D, Bush AI, Lautenschalger NT, Martins RN, Masters CL, Rowe CC, Szoeke C, Taddei K, Ellis KA and the AIBL Research Group (2012) Predictors of rapid cognitive decline in Alzheimer’s disease: results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing. International Psychogeriatrics, 24: 197-204.

Steinberg S et al. [including Jablensky A] (2012) Common variant at 16q11.2 conferring risk of psychosis. Molecular Psychiatry doi:10.1038/mp.2012.157

Streltsov VA, James S, de Jonge M, Howard D, Paterson D, Sankovich S, Caine J (2012) Imaging of beta-amyloid metal binding in yeast with x-ray fluorescence microscopy. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 8: 657-658.

Svendal G, Berk M, Pasco JA, Jacka FN, Lund A, Williams LJ (2012) The use of hormonal contraceptive agents and mood disorders in women. Journal of Affective Disorders, 140: 92-96.

Tang B, Dean B, Thomas EA (2012) Differential age- and disease-related effects of the expression of genes related to the arachidonic acid signaling pathway in schizophrenia, Psychiatry Research, 196: 201-206.

Toye C, Robinson A L, Jiwa M, Andrews S, McInerney F, Horner B, Holloway K, and Stratton B. Developing and testing a strategy to enhance a palliative approach and care continuity for people who have dementia: study overview and protocol. BMC palliative care 11: 4.

Villemagne VL, Klunk WE, Mathis CA, Rowe CC, Brooks DJ, Hyman BT Ikonomovic et al (2012) A-[beta] imaging: feasible, pertinent and vital to progress in Alzheimer’s disease. European Journal of Nuclear Medicine and Molecular Imaging, 39: 209-219.

Verdile G, Laws SM, Henley D, Ames D, Bush AI, Ellis KA, Faux NG, Gupta VB, Li QX, Masters CL, Pike KE, Rowe CC, Szoeke C, Taddei K, Villemagne VL, Martins RN; for the AIBL Research Group (2012) Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer’s disease. Molecular Psychiatry 23. doi: 10.1038/mp.2012.147.

Villain N, Chetelat G, Grassiot B, P Bourgeat, G Jones, KA Ellis, D Ames, RN Martins, F Eustache, O Salvado, Masters CL, Rowe CC, Villemagne VL (2012) Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB-PET longitudinal study. Brain. 135: 2126-2139.

Villemagne VL, Okamura N, Pejoska S, Drago J, Mulligan RS, Chetelat G, O’Keefe G, Jones G, Kung HF, Pontecorvo M, Masters CL, Skovronsky DM, Rowe CC (2012) Differential Diagnosis in Alzheimer’s Disease and Dementia with Lewy Bodies via VMAT2 and Amyloid Imaging. Neurodegenerative Diseases 10: 161-165.

Villemagne VL, Rowe CC (2012) Long Night’s Journey into the Day: Amyloid-β Imaging in Alzheimer’s Disease. Journal of Alzheimers Disease 33: S349-359.

Williams LJ, Pasco JA, Jacka FN, Dodd S, Berk M (2012) Pain and the relationship with mood and anxiety disorders and psychological symptoms. Journal of Psychosomatic Research, 72: 452-456.




Badcock P B, Moore E, Williamson E, Berk M, Williams L J, Bjerkeset O, Nordahl H M, Patton G C, and Olsson C A (2011) Modeling gene‐environment interaction in longitudinal data: Risk for neuroticism due to interaction between maternal care and the Dopamine 4 Receptor gene (DRD4). Australian journal of psychology 63: 18-25.

Berk M, Johansson S, Wray NR, Williams L, Olsson C, Haavik J, Bjerkeset O (2011) Glutamate cysteine ligase (GCL) and self reported depression: an association study from the HUNT. Journal of Affective Disorders, 131: 207-213.

Berk M, Malhi GS (2011) Should antipsychotics take pole position in mania treatment? Lancet, 378: 1279-1281.

Berk M, Brnabic A, Dodd S, Kelin K, Tohen M, Malhi G S, Berk L, Conus P, and McGorry P D. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar disorders, 13: 87-98.

Caine JM,  Bharadwaj PR, SankovichSE, Ciccotosto GD, Streltsov VA, Varghese JN (2011) Oligomerization and toxicity of Aβ fusion proteins. Biochemical and Biophysical Research Communications, 409 (3), 477-482.

Conn CE, Mulet X, Moghaddam M, Darmanin C, Waddington LJ, Sagnella SM, Kirby N, Varghese JN, Drummond CJ (2011) Enhanced uptake of an integral membrane protein, the dopamine D2L receptor, by cubic nanoparticles doped with Ni chelated EDTA amphiphiles. Soft Matter, 7: 567-578.

Dilanian RA, Darmanin C, Varghese JN, Wilkins SW, Oka T, Yagi N, Quiney HM, Nugent KA (2011) Structural analysis of two-dimensional membrane protein crystals using x-ray powder diffraction data. Protein Science, 20: 457-464.

Gupta V, Wilson A, Rainey-Smith S, Laws S, Bush A, Ellis K, Macaulay L, Rowe C, Szoeke C, Taddei K, Ames D, Masters C, Martins R et al (2011) Establishing apolipoprotein E as a biomarker for Alzheimer’s disease: Australian Imaging, Biomarker and Lifestyle (AIBL) flagship study of ageing. Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association, 8: 110-111.

Hung LW, Villemagne VL, Cheng L et al (2012) The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor cognitive functions in multiple animal models of Parkinson’s disease. Journal of Experimental Medicine, accepted.

Jacka, F. N., Pasco, J. A., Mykletun, A., Williams, L. J., Nicholson, G. C., Kotowicz, M. A., & Berk, M. (2011). Diet quality in bipolar disorder in a population-based sample of women. Journal of affective disorders, 129(1), 332-337.

Laws S, Lam CP, Mondal A, Bush A, Ellis K, Macaulay L, Rowe C, Taddei K, Szoeke C, Ames D, Masters C, Martins R (2011) Gene combination associations with Alzheimer’s disease risk and quantitative traits in the AIBL study. Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association, 8: 678-679.

Laws S, Bender S, Rainey-Smith S, Wilson A, Gupta V, de Ruyck K, Bush A et al (2011) Alzheimer’s Disease – related changes in plasma cortisol levels and gene involvement in the AIBL study. Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association, 8: 407.

Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M (2011) N-acetylcysteine for major depressive episodes in bipolar disorder. Revista Brasileira de Psiquiatria, 33: 374-378.

Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, and Berk M (2011) N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. Journal of affective disorders 129:317-320.

Rainey-Smith S, Brown B, de Ruyck K, Laws S, Wilson A, Gupta V, Ames D, Ellis K, Taddei K, Head R, Macaulay L, Masters C, Rowe C, Szoeke C, Martins R et al (2011) Alzheimer’s disease related changes in plasma brain-derived neurotropic factor levels. Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association, 8: 407-408.

Williams LJ, Brennan SL, Henry MJ, Berk M, Jacka FN, Nicholson GC, Kotowicz MA, Pasco JA (2011) Area-based socioeconomic status and mood disorders: cross-sectional evidence from a cohort of randomly selected adult women. Maturitas, 69: 173-178.

Williams LJ, Pasco JA, Jacka FN, Henry MJ, Dodd S, Nicholson GC, Kotowicz MA, Berk M (2011) Bipolar disorder and adiposity: a study using whole body dual energy X-ray absorptiometry scans. Acta Neuropsychiatrica, 23: 219-223.